

ASX ANNOUNCEMENT

30 November 2021

DurAVR™ THV featured at PCR London Valves 2021

Brisbane, Australia and Minneapolis, USA, Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company), is pleased to announce that its unique 3D single-piece Transcatheter Heart Valve (DurAVR™) has been presented in the innovation section of PCR London Valves 2021.

PCR London Valves is the world's largest educational conference focused on transcatheter therapies for valvular heart disease. This year's edition took place on 21-23 November 2021 and attracted over 3,600 attendees including interventional cardiologists, cardiac surgeons, imaging specialists and industry partners committed to the field of structural heart solutions.

For the second consecutive year, Anteris' novel transcatheter device, which is designed for lifetime patient management, was the only aortic valve featured in the innovation section. "DurAVR™ heart valve has the potential to deliver a functional cure in the treatment of severe aortic stenosis. Our focus is on developing next-generation technologies that create life-changing outcomes for patients," said Wayne Paterson, Chief Executive Officer of Anteris.

DurAVR™ THV was presented by Dr. Christopher Meduri, an internationally recognised interventional cardiologist at Karolinska University Hospital in Stockholm (Sweden) and Anteris' recently appointed Chief Medical Officer (CMO). Throughout his career, Dr. Meduri has successfully performed over 1,700 TAVR (transcatheter aortic valve replacement) procedures and is passionate about providing novel therapies and optimising care of patients with valvular heart disease.

Dr. Meduri highlighted the features and benefits of the transcatheter heart valve, as well as its bench and pre-clinical studies results aiming at proving valve preservation and near normal pre-disease hemodynamics. Essentially, he concluded that:

- DurAVR™ THV is designed to address the current gaps in TAVR therapy, especially in younger patients, with longer life expectancy and active lifestyle;
- Patented anti-calcification tissue treatment has proven to be superior to other tissues treatments currently available;
- Bench and animal studies demonstrate excellent durability and superior hemodynamics.

Anteris' innovative 3D single-piece transcatheter heart valve was also displayed in e-posters: "New TAVR device shows excellent durability and hemodynamic performance in pre-clinical study"; as well as the Expert Interview section: "The science behind a valve designed for life" highlighting the DurAVR™'s potential to revolutionise the TAVR space".

"We are thrilled by the interest we received for DurAVR™ at PCR London Valves. This is one of the most important medical conferences of the year and is keenly watched by physicians, analysts, and industry executives. With our first-in-human study now under way, we anticipate even more profile for the Company in 2022 at the major medical conferences," CEO Wayne Paterson concluded.

ENDS

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



For personal use only

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Our focus is on developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris Technologies Ltd's DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of tomorrow's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Hannah Howlett

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 4 5064 8064

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech

For personal use only